JT. Schouten, Protease inhibitors., in STEP Perspect, vol. 7, n. 3, 1995, pp. 12-3, PMID11362981.
N. Tachikawa, [Protease inhibitors]., in Kansenshogaku Zasshi, vol. 79, n. 12, Dec 2005, pp. 905-30, PMID16444973.
S. Vella, Update on HIV protease inhibitors., in AIDS Clin Care, vol. 7, n. 10, Oct 1995, pp. 79-82, 88, PMID11362832.
GJ. Moyle, D. Back, Principles and practice of HIV-protease inhibitor pharmacoenhancement., in HIV Med, vol. 2, n. 2, Apr 2001, pp. 105-13, PMID11737387.
EP. Acosta, Pharmacokinetic enhancement of protease inhibitors., in J Acquir Immune Defic Syndr, 29 Suppl 1, Feb 2002, pp. S11-8, PMID11832697.
RC. Rathbun, DR. Rossi, Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement., in Ann Pharmacother, vol. 36, n. 4, Apr 2002, pp. 702-6, PMID11918523.
C. Merry, MG. Barry; F. Mulcahy; M. Ryan; J. Heavey; JF. Tjia; SE. Gibbons; AM. Breckenridge; DJ. Back, Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients., in AIDS, vol. 11, n. 4, Mar 1997, pp. F29-33, PMID9084785.
DJ. Kempf, KC. Marsh; JF. Denissen; E. McDonald; S. Vasavanonda; CA. Flentge; BE. Green; L. Fino; CH. Park; XP. Kong, ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans., in Proc Natl Acad Sci U S A, vol. 92, n. 7, Mar 1995, pp. 2484-8, PMID7708670.
J. Sahai, Risks and synergies from drug interactions., in AIDS, 10 Suppl 1, Nov 1996, pp. S21-5, PMID8970672.
GN. Kumar, AD. Rodrigues; AM. Buko; JF. Denissen, Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes., in J Pharmacol Exp Ther, vol. 277, n. 1, Apr 1996, pp. 423-31, PMID8613951.
M. Barry, S. Gibbons; D. Back; F. Mulcahy, Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations., in Clin Pharmacokinet, vol. 32, n. 3, Mar 1997, pp. 194-209, PMID9084959.
MV. Bochet, C. Jacquiaud; MA. Valantin; C. Katlama; G. Deray, Renal insufficiency induced by ritonavir in HIV-infected patients., in Am J Med, vol. 105, n. 5, Nov 1998, p. 457, PMID9831435.
JM. Llibre, J. Romeu; E. López; G. Sirera, Severe interaction between ritonavir and acenocoumarol., in Ann Pharmacother, vol. 36, n. 4, Apr 2002, pp. 621-3, PMID11918509.
GK. Dresser, JD. Spence; DG. Bailey, Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition., in Clin Pharmacokinet, vol. 38, n. 1, Jan 2000, pp. 41-57, PMID10668858.
Y. Kato, T. Fujii; N. Mizoguchi; N. Takata; K. Ueda; MD. Feldman; SR. Kayser, Potential interaction between ritonavir and carbamazepine., in Pharmacotherapy, vol. 20, n. 7, Jul 2000, pp. 851-4, PMID10907977.
EL. Michalets, CR. Williams, Drug interactions with cisapride: clinical implications., in Clin Pharmacokinet, vol. 39, n. 1, Jul 2000, pp. 49-75, PMID10926350.
SC. Piscitelli, DR. Kress; RJ. Bertz; A. Pau; R. Davey, The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine., in Pharmacotherapy, vol. 20, n. 5, maggio 2000, pp. 549-53, PMID10809341.
F. Jover, JM. Cuadrado; L. Andreu; J. Merino, Reversible coma caused by risperidone-ritonavir interaction., in Clin Neuropharmacol, vol. 25, n. 5, pp. 251-3, PMID12410055.
GJ. Muirhead, MB. Wulff; A. Fielding; D. Kleinermans; N. Buss, Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir., in Br J Clin Pharmacol, vol. 50, n. 2, Aug 2000, pp. 99-107, PMID10930961.
A. Zalma, LL. von Moltke; BW. Granda; JS. Harmatz; RI. Shader; DJ. Greenblatt, In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors., in Biol Psychiatry, vol. 47, n. 7, Apr 2000, pp. 655-61, PMID10745059.
KR. Knoell, TM. Young; ES. Cousins, Potential interaction involving warfarin and ritonavir., in Ann Pharmacother, vol. 32, n. 12, Dec 1998, pp. 1299-302, PMID9876810.
R. Sannerstedt, P. Lundborg; BR. Danielsson; I. Kihlström; G. Alván; B. Prame; E. Ridley, Drugs during pregnancy: an issue of risk classification and information to prescribers., in Drug Saf, vol. 14, n. 2, Feb 1996, pp. 69-77, PMID8852521.